Lv7
3370 积分 2021-09-09 加入
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
23天前
已完结
Trispecific anti-CLDN-18.2/CD3/CD28 antibodies for gastric cancer treatment
24天前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
24天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
24天前
已完结
Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas
1个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
1个月前
已完结
Tarlatamab in Small-Cell Lung Cancer
1个月前
已完结
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
1个月前
已完结
Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma
1个月前
已完结
皖公网安备34019202002308
